---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-060121"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:42:19.962498+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ImmuCell reports preliminary Q2 sales of $5.47M, up 55% YoY; H1 sales up 82%

## Summary
- Q2 2024 preliminary sales $5.47M vs $3.53M in Q2 2023, a 55% increase.
- Six-month sales $12.73M, up 82% from $6.98M; twelve-month sales $23.22M, up 48%.
- Backlog of orders as of June 30, 2024: approx. $8.93M.
- Production output at 74% of $30M full capacity in Q2; goal to produce $14M in H2 to reach ~95%.
- Still working on FDA approval for Re-Tain; expect fourth CMC submission after manufacturer issues resolved.

## SEC filing metadata
- accession: 0001213900-24-060121
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390024060121/0001213900-24-060121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390024060121/ea0209162-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-060121
- JSON: https://secwatch.observer/filing/0001213900-24-060121.json
- Plain text: https://secwatch.observer/filing/0001213900-24-060121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.